DAP_CAT

Epidemiologic Research Group in Diabetes from Primary Health Care

The research team is made up of professionals from various disciplines and we focus our research on the study of diabetes and its complications, both in hospitals and primary care. The group has shown a great capacity to generate projects and publications in recent years.

The group's main lines of research are twofold: a) Complications of diabetes: atherosclerosis and microvascular disease, as the main causes of morbidity and mortality b) Epidemiology of diabetes: research in primary care and use of large databases. In recent years, the group has developed projects using the SIDIAP database on different aspects of diabetes in real-world evidence.

The group is a pioneer at the Spanish level in this area, and has active collaborations with international groups. In the last 5 years, the group has published 312 articles, of which 171 are in Q1 (55%) and 47 in D1 (15%). The average impact factor of articles is 6,552 and 11,190 citations.

Group projects​​​​​

• La Retinopatia Diabètica com a predictor de la morbilitat cardiovascular i la mortalitat en pacients amb Diabetis tipus 2. ICS - Institut Català de la Salut. 2021-2025. IP: Joan Francesc Barrot de la Puente.
• Pipa 2024: Programa Integrat De Promoció De La Vacunació Antigripal Al Cap Sanllehy (2024). ICS - Institut Català de la Salut. 2024-2025. IP: Carolina Lapena Estella.
• Caracterizació de subgrups en la diabetes tipus 2 (T2DM) al diagnòstic, un pas necessari cap a la medicina de precisió en diabetes. Estudi COPERNICAN. (STARFIELD-23/2). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2027. IP: Josep Franch Nadal,Berta Fernandez Camins.
• Biomarcadores séricos de fibrosis hepática y su efecto sobre la morbimortalidad en sujetos con factores de riesgo de esteatosis hepática metabólica: análisis poblacional de la base de datos SIDIAP. 2024-2027. IP: Bogdan Vlacho Vlacho.
• Estudio sobre la importancia de los primeros años después del diagnóstico de una diabetes mellitus tipo 2 sobre el grado de control metabólico, manejo del paciente, costes sanitarios y la carga económica asociada al tratamiento del paciente. Estudio HEBE-T2DM. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2026. IP: Josep Franch Nadal.
• Estudio epidemiológico de caracterización del riesgo trombótico entre las personas con fibrilación auricular y diabetes mellitus. Estudio epiFADM.cat. 2024-2027. IP: Josep Franch Nadal.
• Prevalencia, incidencia, factores de riesgo y complicaciones relacionadas con la disfunción eréctil entre las personas con diabetes mellitus tipo 2 en la base de datos de atención primaria SIDIAP-Estudio epiDEDM2cat. 2023-2026. IP: Bogdan Vlacho Vlacho.
• A pivotal multi-centre, open-label, two-part clinical investigation confirming the safety and accuracy of the Glyconics-DS in assessment of glycated nail keratin in individuals with unknown diabetes status and performance evaluation of the Glyconics SW package delivering the dichotomised results in Catalonia (Spain). (DAP-NIRDM-2023-04). GLYCONICS LTD. 2023-2024. IP: Francesc Xavier Cos Claramunt.Estudio de la epidemiología y la evolución de la Enfermedad Renal Crónica en las personas con DM2 respecto a la población no diabética. Estudio epiERC_DM2.cat. 2023-2026. IP: Josep Franch Nadal.
• Evolución de la enfermedad renal en las personas con DM2 según los valores iniciales de filtrado glomerular y el tratamiento antidiabético. Estudio epiERDM2.cat. (PI22/00989). Instituto de Salud Carlos III. 2023-2025. IP: Joan-Antoni Vallès Callol.
• Sobrecarga en cuidadores/as informales de personas atendidas en el domicilio por Atención Primaria durante la pandemia por covid 19: estudio de metodología mixta. 2022-2025. IP: Carolina Lapena Estella.
• Aportacions de la genètica a la caracterització de una cohort de Medicina Personalitzada de Precisió en el moment del debut de la diabetis. (SLT021/21/000030). Generalitat Catalunya. 2022-2025. IP: Josep Franch Nadal.
• Global and country-specific rates and trends in the incidence of diagnosed type 2 diabetes (GLOBALDIAB). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022-2024. IP: José Manuel Mata Cases.
• Caracterización de subgrupos de diabetes mellitus tipo 2 al diagnóstico: un paso necesario hacia la medicina de precisión en diabetes, estudio COPERNICAN. Institut Recerca Hospital Santa Creu i Sant Pau. 2021-2026. IP: Dídac Mauricio Puente.
• Gestational diabetes and complications among pregnant women attended in primary care sexual and reproductive health services in Catalonia. Primary Care Diabetes Europe. 2021-2024. IP: Josep Franch Nadal.
• ImpactT2D: una estrategia genómica para implementar medicina de precisión en la diabetes tipo 2. (PMP21/00102). Instituto de Salud Carlos III. 2021-2025. IP: Josep Franch Nadal.
• Evolución de control metabólico de la diabetes tipo 2 en atención primaria de Cataluña. ICS - Institut Català de la Salut. 2021-2024. IP: José Manuel Mata Cases.
• Identificación de Factores predictores de Mal Pronóstico identificables ya en el momento del diagnóstico de la COVID-19 en Atención Primaria. ¿Varían en cada una de las ondas epidémicas?. (PI21/01318). Instituto de Salud Carlos III. 2021-2024. IP: José Manuel Mata Cases,Joan Francesc Barrot de la Puente.
• A Real-World Database Study of Canagliflozin Utilization in Type 1 Diabetes Patients Over Time among European Countries. Janssen Research & Development, LLC. 2021-2024. IP: Josep Franch Nadal. ContRol de la diabEteS tipo 2 En tIempoS de pandemia COVID-19 en centros de aTención primaria. Estudio RESIST. Redgedaps, s.l. 2021-2024. IP: Josep Franch Nadal.
• A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients who Initiated Exenatide as Compared with those who Initiated Other non-Glucagon-Like Peptide 1 Receptor Agonists based Glucose Lowering Drugs (EXCEED). IQVIA LTD. 2020-2025. IP: Josep Franch Nadal.

Group publications

• Rivière JG, Carot Sans G, Piera Jiménez J, de la Torre S, Cos X, Serra Picamal X et al. Development of an Expert-Based Scoring System for Early Identification of Patients with Inborn Errors of Immunity in Primary Care Settings - the PIDCAP Project. J Clin Immunol. 2025;45(1):26-26. PMID:39432052.
• Orozco Beltran D, Mata Cases M, Artola Menéndez S, Álvarez Guisasola F, Cebrián Cuenca AM, Pérez A et al. Glycemic and weight control in people with type 2 diabetes: A real-world observational study in primary care. Prim Care Diabetes. 2025;19(1):7-14. PMID:39741072.
• Fernandez Camins B, Vlacho B, Canudas A, Ortega M, Granado Casas M, Perera LLuna A et al. Characterisation of type 2 diabetes subgroups at diagnosis: the COPERNICAN prospective observational cohort study protocol. BMJ Open. 2024;14(12):PMID:39675821.
• Hernández Teixidó C, de la Puente JB, Jiménez SM, Fernández Camins B, Mauricio D, Aroca PR et al. Incidence of Diabetic Retinopathy in Individuals with Type 2 Diabetes: A Study Using Real-World Data. J Clin Med. 2024;13(23):PMID:39685542.
• Antentas M, Rojo López MI, Vendrell P, Granado Casas M, Genua I, Fernandez Camins B et al. Impact of Dietary Niacin on Metabolic Dysfunction-Associated Steatotic Liver Disease in Mediterranean Subjects: A Population-Based Study. Nutrients. 2024;16(23). PMID:39683571.
• Magliano DJ, Chen L, Morton JI, Salim A, Carstensen B, Gregg EW et al. Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium. Lancet Diabetes Endocrinol. 2024;12(12):915-923. PMID:39541997.
• Cabré JJ, Barrio F, Vizcaíno J, Martínez A, Mur T, Sagarra R et al. Results of the implementation of the DP-TRANSFERS project in Catalonia: a translational method to improve diabetes screening and prevention in primary care. Rev Clin Esp (Barc). 2024;224(9):569-579. PMID:39216807.
• Lago Sampedro A, Oualla Bachiri W, García Serrano S, Maldonado Araque C, Valdés S, Doulatram Gamgaram V et al. Protective Effect of High Adherence to Mediterranean Diet on the Risk of Incident Type-2 Diabetes in Subjects with MAFLD: The Di@bet.es Study. Nutrients. 2024;16(21):PMID:39519621.
• Rojo López MI, Bermúdez López M, Castro E, Farràs C, Torres G, Pamplona R et al. Mediterranean Diet Is a Predictor of Progression of Subclinical Atherosclerosis in a Mediterranean Population: The ILERVAS Prospective Cohort Study. Nutrients. 2024;16(21):PMID:39519440.
• García Diego DA, Badia X, Benítez Hidalgo O, Jiménez V, Juárez JC, Núñez R et al. Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi-criteria decision analysis. Haemophilia. 2024;30(6):1281-1287. PMID:39340327.
• Ortega E, Genua I, Mata Cases M, Roqué M, Vlacho B, Real Gatius J et al. First manifestation of cardiovascular disease according to age and sex in a Mediterranean country. Front. Cardiovasc. Med. 2024;111403363-1403363. PMID:39355347.
• Ramírez Morros A, Berenguera A, Millaruelo L, Buil Cosiales P, Gomez Garcia C, Cos X et al. Impact of Gender on Patient Experiences of Self-Management in Type 2 Diabetes: A Qualitative Study. Patient Prefer. Adherence. 2024;181885-1896. PMID:39290823.
• Badia X, Calleja MA, Escudero Vilaplana V, Pérez Martínez A, Piñana JL, Poveda JL et al. The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). Orphanet J. Rare Dis. 2024;19(1):PMID:39180132.
• Vlacho B, Molló Iniesta À, Gratacòs M, Mata Cases M, Rubinat E, Berenguera A et al. Effectiveness of a multicomponent healthcare intervention on blood pressure and lipids among subjects with poorly controlled type 2 diabetes: Findings from the INTEGRA study. Prim Care Diabetes. 2024;18(4):402-408. PMID:38782704.
• López Jiménez T, Plana Ripoll O, Duarte Salles T, Recalde M, Bennett M, Xavier Cos F et al. Exploring the association between metabolic syndrome, its components and subsequent cancer incidence: A cohort study in Catalonia. Cancer Med. 2024;13(16):PMID:39149842.
• Vlacho B, Bundó M, Llussà J, Real J, Mata Cases M, Cos X et al. Diabetic foot disease carries an intrinsic high risk of mortality and other severe outcomes in type 2 diabetes: a propensity score-matched retrospective population-based study. Cardiovasc Diabetol. 2024;23(1):209-209. PMID:38898525.
• Gomis Pastor M, Berdún J, Borrás Santos A, López AD, Rama BFM, García Esquirol O et al. Clinical Validation of Digital Healthcare Solutions: State of the Art, Challenges and Opportunities. Healthcare (Basel). 2024;12(11):PMID:38891132.
• Jiménez A, Vlacho B, Mata Cases M, Real J, Mauricio D, Franch Nadal J et al. Sex and age significantly modulate cardiovascular disease presentation in type 2 diabetes: a large population-based cohort study. Front Endocrinol (Lausanne). 2024;151344007-1344007. PMID:38828412.
• Mouriño Ruiz R, Serral G, Continente X, López MJ, Lapena C, Puigpinós Riera R. Evaluation of effectiveness of an art-based museum intervention in reducing loneliness among older adults (ArtGran): a quasi-experimental study. Public Health. 2024;230149-156. PMID:38552347.
• Romero Aroca P, Verges R, Pascual Fontanilles J, Valls A, Franch Nadal J, Mundet X et al. Referable Diabetic Retinopathy Prediction Algorithm Applied to a Population of 120,389 Type 2 Diabetics over 11 Years Follow-Up. Diagnostics. 2024;14(8):PMID:38667478.
• Ajjan RA, Battelino T, Cos X, Del Prato S, Philips JC, Meyer L et al. Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2024;20(7):426-440. PMID:38589493.
• Barranco Altirriba M, Alonso N, Weber RJM, Lloyd GR, Hernandez M, Yanes O et al. Lipidome characterisation and sex-specific differences in type 1 and type 2 diabetes mellitus. Cardiovasc Diabetol. 2024;23(1):109-109. PMID:38553758.
• Vlacho B, Fernandez Camins B, Canudas Ventura A, Rodríguez A, Mollo A, Claramunt FXC et al. Performance of Primary Care Physicians in the Management of Glycemia, Lipids, and Blood Pressure among People with Type 2 Diabetes: A Cross-Sectional Study. J Clin Med. 2024;13(6):PMID:38541770.
• Soldevila B, Alarcon L, Vlacho B, Real J, Hernandez M, Cos X et al. Trends in the prevalence of gestational diabetes in Catalonia from 2010 to 2019. Prim Care Diabetes. 2024;18(2):169-176. PMID:38228411.
• Ramirez Morros A, Franch Nadal J, Real J, Miro Catalina Q, Bundo M, Vlacho B et al. Clinical characteristics and degree of cardiovascular risk factor control in patients with newly-diagnosed type 2 diabetes in Catalonia. Front Endocrinol (Lausanne). 2024;151339879-1339879. PMID:38390201.
• Benitez O, García Diego DA, Jiménez Yuste , Juarez JC, Núñez R, Perez Santamarina R et al. Value contribution of etranacogene dezaparvovec for the treatment of severe and moderately severe haemophilia b in spain through multicriteria decision analysis (MCDA). Value Health. 2024;27(12):
• Amado Guirado E, Gómez Peralta F, Balea FJ, Barrot J, Lorenzo Herrero S, Pascual et al. Reducing complications in patients living with type 2 diabetes by an optimized management of weight and glycemia and their associated savings. Value Health. 2024;27(12):336-336.
• Wang D, Callol J. Evolution of the antidiabetic drugs use in Catalonia from 2015 to 2023. Basic Clin. Pharmacol. Toxicol. 2024;13549-49.
• Colomer M, Callol J, Liz EF, Barchilon GB, Ley S, Wang D et al. The Comptagotes, a newsletter on pharmacotherapeutic updates in primary care: What do we publish?. Basic Clin. Pharmacol. Toxicol. 2024;13560-60.
• Peraile MA, Rojo López MI, Vlacho B, Rossell J, Vendrell P, Genua I et al. Sex-specific disparities in dietary patterns and their association with metabolic-associated fatty liver disease. Eur. J. Clin. Invest. 2024;54.
• Diego D, Jiménez Yuste V, Vazquez RN, Hidalgo OB, Poveda JL, Giménez JCJ et al. Value contribution of Etranacogene dezaparvovec for the treatment of severe and moderately severe haemophilia B in Spain through multicriteria decision analysis (MCDA). Haemophilia. 2024;3062-62.
• Paldánius PM, Choudhary P, Lazaro Pacheco D, Salter J, Cos X. Miniaturised near-infrared device for diabetes screening. Diabetes Technol. Ther. 2024;26299-299.